IMV Announces Annual and Special Meeting of Shareholders Voting Results
11 May 2019 - 12:18AM
Business Wire
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immunotherapy
company (or the ”Corporation”), today announced the voting results
from its Annual and Special Meeting of Shareholders held
on Thursday May 9, 2019.
Based on the proxies received and the votes on a show of
hands, all resolutions were accepted including the election of
Directors for whom details of the votes are as follows;
Name of Nominee Votes cast FOR
% of votes cast FOR
Julia Gregory 26,089,068 99.90% James H. Hall 22,672,109 86.82%
Frederic Ors 26,090,880 99.91% Wayne Pisano 25,871,567 99.07%
Albert Scardino 26,080,889 99.87% Andrew Sheldon 19,660,721 75.29%
Shermaine Tilley 25,867,251 99.05% Markus Warmuth 25,989,068 99.52%
Shareholders also approved the appointment of
PricewaterhouseCoopers, LLP, Chartered Accountants, as independent
auditor of the Corporation for the ensuing year and that Directors
be authorized to fix their remuneration.
In addition, all amendments to the stock option plan as
described in schedule A of the circular dated March 21, 2019 were
accepted as well as the ratification of options to officers of the
Corporation in the form set out in schedule B of the circular.
About IMV
IMV Inc. is a clinical stage biopharmaceutical company dedicated
to making immunotherapy more effective, more broadly applicable,
and more widely available to people facing cancer and other serious
diseases. IMV is pioneering a new class of immunotherapies based on
the Company’s proprietary drug delivery platform. This patented
technology leverages a novel mechanism of action that enables the
programming of immune cells in vivo, which are aimed at
generating powerful new synthetic therapeutic capabilities. IMV’s
lead candidate, DPX-Survivac, is a T cell-activating immunotherapy
that combines the utility of the platform with a target: survivin.
IMV is currently assessing DPX-Survivac as a monotherapy in
advanced ovarian cancer, as well as a combination therapy in
multiple clinical studies with Merck. Connect
at www.imv-inc.com
IMV Forward-Looking Statements
This press release contains forward-looking information under
applicable securities law. All information that addresses
activities or developments that we expect to occur in the future is
forward-looking information. Forward-looking statements are based
on the estimates and opinions of management on the date the
statements are made. However, they should not be regarded as a
representation that any of the plans will be achieved. Actual
results may differ materially from those set forth in this press
release due to risks affecting the Corporation, including access to
capital, the successful completion of clinical trials and receipt
of all regulatory approvals. IMV Inc. assumes no
responsibility to update forward-looking statements in this press
release except as required by law. These forward-looking statements
involve known and unknown risks and uncertainties and those risks
and uncertainties include, but are not limited to, our ability to
access capital, the successful and timely completion of clinical
trials, the receipt of all regulatory approvals and other risks
detailed from time to time in our ongoing quarterly filings and
annual information form. Investors are cautioned not to rely on
these forward-looking statements and are encouraged to read IMV’s
continuous disclosure documents, including its current annual
information form, as well as its audited annual consolidated
financial statements which are available on SEDAR
at www.sedar.com and on EDGAR
at www.sec.gov/edgar.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190510005307/en/
INVESTOR RELATIONS:
Marc Jasmin, Senior Director, Investor Relations and
CommunicationsO: (902) 492-1819 ext : 1042M: (514) 917-9481 E:
mjasmin@imv-inc.com
MEDIA:
Andrea Cohen, Sam Brown Inc.O: (917) 209-7163
E: andreacohen@sambrown.com
IMV (TSX:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IMV (TSX:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024